At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
MM-121 +1 moredrug
Likely dose
Paclitaxel 80 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
In Brief
A Phase 1 clinical trial evaluating MM-121 and Paclitaxel for Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer, and 2 related conditions. Completed, enrolled 41 participants across 5 sites.
Detailed Summary
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
CountriesUnited States
CollaboratorsSanofi
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionMay 2014
Study CompletionJul 2014
TodayJul 2026
First PostedSep 27, 2010
Enrollment StartOct 1, 2010
Primary CompletionMay 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.8 years ago
Interventions
MM-121drug
increasing doses of MM-121 IV QW
Paclitaxeldrug
Paclitaxel - 80 mg/m2 IV QW